Combination MDMA and Psilocybin Administration Risks

Introduction to Risks

• The administration of 100mg MDMA followed by 3g psilocybin 45 minutes later is not recommended due to unpredictable pharmacological interactions with potentially dangerous cardiovascular, neurohormonal, and psychological effects, according to the Journal of Clinical Oncology 1

Critical Safety Concerns

• No published studies exist examining the sequential administration of MDMA followed by psilocybin at these doses, highlighting a significant lack of evidence base, as noted by Neuroscience and Biobehavioral Reviews 2 and the Journal of Clinical Oncology 1
• Psychedelic-assisted therapy guidelines, such as those from the American Academy of Child and Adolescent Psychiatry, reference these substances separately, never in combination, emphasizing the need for caution 1
• The combined cardiovascular burden of MDMA and psilocybin is unpredictable and potentially dangerous, particularly given MDMA's contraindication in patients with symptomatic cardiovascular disease, as stated by the Journal of the American Academy of Child and Adolescent Psychiatry 4 and 5
• Psilocybin increases heart rate and blood pressure, which can exacerbate the cardiovascular risks associated with MDMA, according to Neuroscience and Biobehavioral Reviews 2 and 3

Contraindicated Patient Populations

• Stimulants, including those with stimulant properties like MDMA, are contraindicated in patients with schizophrenia, psychosis NOS, or manic episodes with psychosis, as indicated by the Journal of the American Academy of Child and Adolescent Psychiatry 4 and 5
• Patients with a history of mental health issues may represent an absolute contraindication for MDMA-assisted therapy, as suggested by the Journal of the American Academy of Child and Adolescent Psychiatry 4

Evidence-Based Alternatives

• Psilocybin therapy uses separate protocols with doses typically ranging from 10-30mg pure psilocybin, which is a more established and safer approach, according to Neuroscience and Biobehavioral Reviews 2 and the Journal of Clinical Oncology 1
• MDMA-assisted therapy for PTSD uses 75-150mg total dose in controlled settings, with a more predictable and safer profile, as noted by Neuroscience and Biobehavioral Reviews 2

Common Pitfalls to Avoid

• Anecdotal reports should not be used to proceed with combination therapy, as they do not reflect actual pharmacological safety, and may be subject to expectancy effects and placebo responses, as highlighted by Neuroscience and Biobehavioral Reviews 2, 3, and 6